Access & Coverage

Comprehensive access to a well-supported therapy

  • An affordable option with extensive coverage
    • The majority of patients with commercial insurance are
  • The majority of eligible patients have $0 co-pay with the EXTAVIA Co-Pay Support Program from Novartis
    • Out-of-pocket costs are covered up to $9,300 per year, regardless of income level or medical history§
  • EXTAVIA saves your patients almost 1 prescription per year compared with Betaseron®
    • Patients receive 15 vials of EXTAVIA with each prescriptionenough medicine for 30 days of treatmentcompared with 14 vials for Betaseron1,2
  • Additional assistance from Novartis
    • The Novartis Patient Assistance Program provides access to free medicinal products for eligible low-income, uninsured patients||
    • Referrals to other financial aid and patient assistance programs
      • Patient Assistance Now from Novartis helps patients gain access to other financial assistance programs and organizations

As of October 2019.

§Limitations apply. Valid only for those with commercial insurance. Offer not valid under Medicare, Medicaid, or any other federal or state program. Not valid for cash-paying patients, where product is not covered by patient’s commercial insurance, or where plan reimburses you for entire cost of your prescription drug. Offer is not valid where prohibited by law. Valid only in the US and Puerto Rico. This program is not health insurance. Offer may not be combined with any other rebate, coupon, or offer. Patient certifies responsibility for complying with applicable limitations, if any, of any commercial insurance and reporting receipt of program rewards, if necessary, to any commercial insurer. This program is subject to termination or modification at any time.

||To qualify, patients must be US residents, receive an income less than 500% of the Federal Poverty Level, and must not have insurance (public or private) or any third-party prescription coverage.

Back to Top
1. Extavia [Prescribing Information]. East Hanover, NJ: Novartis Pharmaceuticals Corp; 2019. 2. Betaseron [Prescribing Information]. Montville, NJ: Bayer HealthCare Pharmaceuticals Inc; 2016. 3. Kappos L, Polman CH, Freedman MS, et al. Treatment with interferon beta-1b delays conversion to clinically definite and McDonald MS in patients with clinically isolated syndromes. Neurology. 2006;67:1242-1249. 4. Fingertip Formulary®. Analytics report. Extavia: Percentage of covered lives. Accessed October 2019.